Atrion (NASDAQ:ATRI) Sees Strong Trading Volume

Shares of Atrion Co. (NASDAQ:ATRI) saw an uptick in trading volume on Monday . 14,391 shares were traded during mid-day trading, a decline of 23% from the previous session’s volume of 18,792 shares.The stock last traded at $418.86 and had previously closed at $414.95.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded shares of Atrion from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st.

Atrion Stock Down 1.7 %

The company’s 50 day moving average price is $415.83 and its two-hundred day moving average price is $366.56. The stock has a market cap of $721.92 million, a P/E ratio of 37.19 and a beta of 0.62.

Atrion (NASDAQ:ATRI) last posted its quarterly earnings results on Thursday, February 29th. The medical instruments supplier reported $3.65 earnings per share for the quarter. Atrion had a net margin of 11.46% and a return on equity of 8.07%. The firm had revenue of $43.58 million during the quarter.

Atrion Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 29th. Stockholders of record on Friday, March 15th were paid a dividend of $2.20 per share. This represents a $8.80 annualized dividend and a dividend yield of 2.15%. The ex-dividend date of this dividend was Thursday, March 14th. Atrion’s dividend payout ratio is presently 79.78%.

Hedge Funds Weigh In On Atrion

Several institutional investors have recently bought and sold shares of ATRI. Copeland Capital Management LLC lifted its stake in shares of Atrion by 56.4% during the fourth quarter. Copeland Capital Management LLC now owns 86 shares of the medical instruments supplier’s stock worth $33,000 after buying an additional 31 shares during the period. Quadrant Capital Group LLC acquired a new position in Atrion during the fourth quarter valued at $36,000. Harbor Investment Advisory LLC lifted its position in Atrion by 33.1% during the fourth quarter. Harbor Investment Advisory LLC now owns 189 shares of the medical instruments supplier’s stock valued at $72,000 after purchasing an additional 47 shares during the period. Tower Research Capital LLC TRC lifted its position in Atrion by 592.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 270 shares of the medical instruments supplier’s stock valued at $102,000 after purchasing an additional 231 shares during the period. Finally, SG Americas Securities LLC acquired a new position in shares of Atrion in the fourth quarter worth about $108,000. 66.19% of the stock is owned by hedge funds and other institutional investors.

About Atrion

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.